Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack

Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02089074

Enrollment

265

Registered

2014-03-17

Start date

2012-11-30

Completion date

2016-06-30

Last updated

2017-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Attack, Transient, Stroke

Keywords

Secondary Prevention, Pharmacists, Directive Counseling, Medication Adherence, Patient Compliance

Brief summary

Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.

Interventions

BEHAVIORALDrug use counselling

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Probable or possible transient ischemic attack * Residing in Central Norway * Examined within 2 weeks after the onset of symptoms * Modified Rankin Scale 3 or less and living at home * enrolled in the MIDNOR-TIA study NCT02038725 * Informed consent

Design outcomes

Primary

Measure	Time frame	Description
adherence to drug treatment in secondary prevention after TIA	3 months	self reporting of adherence

Secondary

Measure	Time frame	Description
adherence to drug treatment in secondary prevention after TIA	1 year	self reporting of adherence
Persistence	3 months	Persistence measured by control of filled prescriptions
Incidence of stroke and cardiovascular events and deaths	3 months	Measured by using data from national health registries
degree of disability or dependence in the daily activities	3 months	measured by modified Rankin Scale and indirectly by level of care
patient satisfaction	3 months	Measured by using data from the Norwegian Stroke Registry

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026